Menu

Filtros : "Chile" "Frontiers in Pharmacology" Limpar

Filtros

Refine with date range

  • 1

1 - 4 (4 records)

  • Artigo de periodico

    Polymorphisms in mTOR and calcineurin signaling pathways are associated with long-term clinical outcomes in kidney transplant recipients (2018)

    Salazar, Antony Brayan Campos; Genvigir, Fabiana Dalla Vecchia; Felipe, Claudia R; Silva Junior, Helio Tedesco; Pestana, José O. Medina; Monteiro, Gabriela V; Basso, Rodrigo G; Cerda, Alvaro; Hirata, Mario Hiroyuki ; Hirata, Rosario Dominguez Crespo

    Source: Frontiers in Pharmacology. Unidade: FCF

    Subjects: POLIMORFISMO, TRANSPLANTE DE RIM

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SALAZAR, Antony Brayan Campos et al. Polymorphisms in mTOR and calcineurin signaling pathways are associated with long-term clinical outcomes in kidney transplant recipients. Frontiers in Pharmacology, v. 9, p. 1-11 art. 1296, 2018Tradução . . Disponível em: https://doi.org/10.3389/fphar.2018.01296. Acesso em: 05 maio 2024.

    • APA

      Salazar, A. B. C., Genvigir, F. D. V., Felipe, C. R., Silva Junior, H. T., Pestana, J. O. M., Monteiro, G. V., et al. (2018). Polymorphisms in mTOR and calcineurin signaling pathways are associated with long-term clinical outcomes in kidney transplant recipients. Frontiers in Pharmacology, 9, 1-11 art. 1296. doi:10.3389/fphar.2018.01296

    • NLM

      Salazar ABC, Genvigir FDV, Felipe CR, Silva Junior HT, Pestana JOM, Monteiro GV, Basso RG, Cerda A, Hirata MH, Hirata RDC. Polymorphisms in mTOR and calcineurin signaling pathways are associated with long-term clinical outcomes in kidney transplant recipients [Internet]. Frontiers in Pharmacology. 2018 ; 9 1-11 art. 1296.[citado 2024 maio 05 ] Available from: https://doi.org/10.3389/fphar.2018.01296

    • Vancouver

      Salazar ABC, Genvigir FDV, Felipe CR, Silva Junior HT, Pestana JOM, Monteiro GV, Basso RG, Cerda A, Hirata MH, Hirata RDC. Polymorphisms in mTOR and calcineurin signaling pathways are associated with long-term clinical outcomes in kidney transplant recipients [Internet]. Frontiers in Pharmacology. 2018 ; 9 1-11 art. 1296.[citado 2024 maio 05 ] Available from: https://doi.org/10.3389/fphar.2018.01296

  • Artigo de periodico

    From synthesis to characterization of site-selective PEGylated proteins (2019)

    Belén, Lisandra Herrera; Rangel-Yagui, Carlota de Oliveira ; Lissabet, Jorge F. Beltrán; Effer, Brian; Estevez, Manuel Lee ; Pessoa Junior, Adalberto ; Castillo, Rodrigo L; Farías, Jorge Gonzalo

    Source: Frontiers in Pharmacology. Unidade: FCF

    Subjects: PROTEÍNAS, FARMACOLOGIA

    Versão PublicadaAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      BELÉN, Lisandra Herrera et al. From synthesis to characterization of site-selective PEGylated proteins. Frontiers in Pharmacology, v. 10, p. 1-16 art. 1450, 2019Tradução . . Disponível em: https://doi.org/10.3389/fphar.2019.01450. Acesso em: 05 maio 2024.

    • APA

      Belén, L. H., Rangel-Yagui, C. de O., Lissabet, J. F. B., Effer, B., Estevez, M. L., Pessoa Junior, A., et al. (2019). From synthesis to characterization of site-selective PEGylated proteins. Frontiers in Pharmacology, 10, 1-16 art. 1450. doi:10.3389/fphar.2019.01450

    • NLM

      Belén LH, Rangel-Yagui C de O, Lissabet JFB, Effer B, Estevez ML, Pessoa Junior A, Castillo RL, Farías JG. From synthesis to characterization of site-selective PEGylated proteins [Internet]. Frontiers in Pharmacology. 2019 ; 10 1-16 art. 1450.[citado 2024 maio 05 ] Available from: https://doi.org/10.3389/fphar.2019.01450

    • Vancouver

      Belén LH, Rangel-Yagui C de O, Lissabet JFB, Effer B, Estevez ML, Pessoa Junior A, Castillo RL, Farías JG. From synthesis to characterization of site-selective PEGylated proteins [Internet]. Frontiers in Pharmacology. 2019 ; 10 1-16 art. 1450.[citado 2024 maio 05 ] Available from: https://doi.org/10.3389/fphar.2019.01450

  • Artigo de periodico

    Current state of molecular and metabolic strategies for the improvement of L-asparaginase expression in heterologous systems (2023)

    Lefin, Nicolás ; Miranda, Javiera; Beltrán, Jorge F ; Belén, Lisandra Herrera ; Effer, Brian ; Pessoa Junior, Adalberto ; Farías, Jorge Gonzalo ; Zamorano, Mauricio

    Source: Frontiers in Pharmacology. Unidade: FCF

    Subjects: BIOPROCESSOS, EXPRESSÃO GÊNICA

    Versão PublicadaAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      LEFIN, Nicolás et al. Current state of molecular and metabolic strategies for the improvement of L-asparaginase expression in heterologous systems. Frontiers in Pharmacology, v. 14, p. 1-21, 2023Tradução . . Disponível em: https://doi.org/10.3389/fphar.2023.1208277. Acesso em: 05 maio 2024.

    • APA

      Lefin, N., Miranda, J., Beltrán, J. F., Belén, L. H., Effer, B., Pessoa Junior, A., et al. (2023). Current state of molecular and metabolic strategies for the improvement of L-asparaginase expression in heterologous systems. Frontiers in Pharmacology, 14, 1-21. doi:10.3389/fphar.2023.1208277

    • NLM

      Lefin N, Miranda J, Beltrán JF, Belén LH, Effer B, Pessoa Junior A, Farías JG, Zamorano M. Current state of molecular and metabolic strategies for the improvement of L-asparaginase expression in heterologous systems [Internet]. Frontiers in Pharmacology. 2023 ; 14 1-21.[citado 2024 maio 05 ] Available from: https://doi.org/10.3389/fphar.2023.1208277

    • Vancouver

      Lefin N, Miranda J, Beltrán JF, Belén LH, Effer B, Pessoa Junior A, Farías JG, Zamorano M. Current state of molecular and metabolic strategies for the improvement of L-asparaginase expression in heterologous systems [Internet]. Frontiers in Pharmacology. 2023 ; 14 1-21.[citado 2024 maio 05 ] Available from: https://doi.org/10.3389/fphar.2023.1208277

  • Artigo de periodico

    Contribution of microRNAs in chemoresistance to cisplatin in the top five deadliest cancer: an updated review (2022)

    Reyes, Pia Loren ; Saavedra, Nicolás ; Torso, Nadine de Godoy ; Visacri, Marilia Berlofa ; Moriel, Patricia ; Salazar, Luis Antônio

    Source: Frontiers in Pharmacology. Unidade: FCF

    Subjects: FÁRMACOS, MICRORNAS

    Versão PublicadaAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      REYES, Pia Loren et al. Contribution of microRNAs in chemoresistance to cisplatin in the top five deadliest cancer: an updated review. Frontiers in Pharmacology, v. 13, p. 1-19, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2022.831099. Acesso em: 05 maio 2024.

    • APA

      Reyes, P. L., Saavedra, N., Torso, N. de G., Visacri, M. B., Moriel, P., & Salazar, L. A. (2022). Contribution of microRNAs in chemoresistance to cisplatin in the top five deadliest cancer: an updated review. Frontiers in Pharmacology, 13, 1-19. doi:10.3389/fphar.2022.831099

    • NLM

      Reyes PL, Saavedra N, Torso N de G, Visacri MB, Moriel P, Salazar LA. Contribution of microRNAs in chemoresistance to cisplatin in the top five deadliest cancer: an updated review [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-19.[citado 2024 maio 05 ] Available from: https://doi.org/10.3389/fphar.2022.831099

    • Vancouver

      Reyes PL, Saavedra N, Torso N de G, Visacri MB, Moriel P, Salazar LA. Contribution of microRNAs in chemoresistance to cisplatin in the top five deadliest cancer: an updated review [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-19.[citado 2024 maio 05 ] Available from: https://doi.org/10.3389/fphar.2022.831099
  • 1

1 - 4 (4 records)

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024